SUPRAX- cefixime capsule

Land: USA

Språk: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv ingrediens:

CEFIXIME (UNII: 97I1C92E55) (CEFIXIME ANHYDROUS - UNII:XZ7BG04GJX)

Tilgjengelig fra:

PharmPak, Inc.

Administreringsrute:

ORAL

Resept typen:

PRESCRIPTION DRUG

Indikasjoner:

SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated urinary tract infections caused by susceptible isolates of Escherichia coli and Proteus mirabilis . SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with otitis media caused by susceptible isolates of Haemophilus influenzae , Moraxella catarrhalis , and Streptococcus pyogenes. (Efficacy for Streptococcus pyogenes in this organ system was studied in fewer than 10 infections.) Note: For patients with otitis media caused by Streptococcus pneumoniae , overall response was approximately 10% lower for cefixime than for the comparator [see Clinical Studies ( 14)]. SUPRAX is indicated in the treatment of adults and pediatric patients six months of age or older with pharyngitis and tonsillitis caused by susceptible isol

Produkt oppsummering:

SUPRAX ® is available for oral administration in following dosage forms, strengths and packages listed in the table below:

Autorisasjon status:

Abbreviated New Drug Application

Preparatomtale

SUPRAX- CEFIXIME CAPSULE
PHARMPAK, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
SUPRAX® SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR SUPRAX®.
SUPRAX® (CEFIXIME) TABLETS, FOR ORAL USE
SUPRAX® (CEFIXIME) CAPSULES, FOR ORAL USE
SUPRAX® (CEFIXIME) CHEWABLE TABLETS, FOR ORAL USE
SUPRAX® (CEFIXIME) FOR ORAL SUSPENSION
INITIAL U.S. APPROVAL: 1986
RECENT MAJOR CHANGES
Warnings and Precautions, Risk in Patients with Phenylketonuria ( 5.6)
03/2017
INDICATIONS AND USAGE
SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in
the treatment of adults and pediatric
patients six months and older with the following infections:
Uncomplicated Urinary Tract Infections ( 1.1)
Otitis Media ( 1.2)
Pharyngitis and Tonsillitis ( 1.3)
Acute Exacerbations of Chronic Bronchitis ( 1.4)
Uncomplicated Gonorrhea (cervical/urethral) ( 1.5)
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of SUPRAX and other
antibacterial drugs, SUPRAX should be used only to treat infections
that are proven or strongly suspected
to be caused by bacteria. ( 1.6)
DOSAGE AND ADMINISTRATION
Adults: 400 mg daily ( 2.1)
Pediatric patients (6 months and older): 8 mg/kg/day ( 2.2)
DOSAGE FORMS AND STRENGTHS
Film-coated, scored Tablets: 400 mg ( 3)
Capsules: 400 mg ( 3)
Chewable Tablets: 100 mg, 150 mg and 200 mg ( 3)
Oral Suspension: 100 mg/5 mL, 200 mg/5 mL and 500 mg/5 mL ( 3)
CONTRAINDICATIONS
Contraindicated in patients with known allergy to cefixime or other
cephalosporins. ( 4)
WARNINGS AND PRECAUTIONS
Hypersensitivity reactions including shock and fatalities have been
reported with cefixime. Discontinue
use if a reaction occurs. ( 5.1)
_Clostridium difficile _associated diarrhea: Evaluate if diarrhea
occurs. ( 5.2)
Risk in Patients with Phenylketonuria (PKU): Before prescribing SUPRAX
chewable tablets in a patient
with PKU, consider the combined daily amount of phenylalanine from all
sources, including SUPRAX
chewable ta